Nasdaq ikna.

TELA Bio, Inc. (NASDAQ:TELA) reported second-quarter revenue of $7.6 million, up 116% year-over-year. The revenue exceeded the consensus estimate. The loss per share widened from 53 cents to 57 cents.Mar 7, 2023 · Follow. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ... Published on December 20, 2021. Omega Funds, a Boston, MA-based international healthcare venture capital firm focused on delivering impactful medicines to patients, closed its seventh fund with ...BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...IKNA Earnings Date and Information. Ikena Oncology last released its quarterly earnings data on November 9th, 2023. The reported ($0.40) earnings per share …

Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ... Nov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ... Ikena Oncology (NASDAQ:IKNA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better business?We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, …

See All Market Activity. News + Insights. CLOSE

17 avr. 2023 ... BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA ... NASDAQ:IKNA. IKNA Rankings. #5626 Ranked by Market Cap. #614 ...

IKNA Edit my quotes Ikena Oncology, Inc. Common Stock (IKNA) Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Pre-Market Charts NEWS & …BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.Nov 10, 2022 · BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ... (NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Ikena Oncology. stock was originally listed at a price of $28.30 in Mar 29, 2021.DSP Group, Inc. (NASDAQ:DSPG) is the most popular stock in this table. On the other hand Atomera Incorporated (NASDAQ: ATOM ) is the least popular one with only 5 bullish hedge fund positions.BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

29 avr. 2021 ... Switch to the basic mobile site. Facebook wordmark. Video.BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...10 août 2023 ... (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation ...

Nov 18, 2023 · Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value. The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.

BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Fiscal Q3 2023 ended 9/30/23. Fiscal Q3 2023 ended 9/30/23. Get the latest Ikena Oncology Inc (IKNA) real-time quote, historical performance, charts, and other financial …Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value.BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth. BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...

3 mai 2022 ... Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where ...

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...

... (NASDAQ: NTLA), Korro Bio, and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics. Some ...BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...Dow jones falls over 200 points on thursday; the nasdaq and s&p 500 also trade lower. Krispy kreme reports downbeat results for third quarter; energy shares rise by 0.3%. …BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...DSP Group, Inc. (NASDAQ:DSPG) is the most popular stock in this table. On the other hand Atomera Incorporated (NASDAQ: ATOM ) is the least popular one with only 5 bullish hedge fund positions.BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Oct 5, 2022 · BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... 17 avr. 2023 ... BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA ... NASDAQ:IKNA. IKNA Rankings. #5626 Ranked by Market Cap. #614 ...

Near is among the largest full-stack intelligence providers of aggregated anonymized data on people's behavior around places, with 1.6 billion unique user IDs, in over 70 million places across 44 ...IKNA. Ikena Oncology, Inc. 1.6300 +0.0300 +1.87%: TRENDING. 1. ... Both the S&P 500 and the NASDAQ indexes are back within close reach of the peak yearly values hit at the end of July, after their ...Financial Results for the Year Ended December 31, 2022. As of December 31, 2022, Ikena had $156.9 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient ...Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...Instagram:https://instagram. ms earnings datebest stock options brokerstesla bullsxpeng stovk 29 avr. 2021 ... Switch to the basic mobile site. Facebook wordmark. Video. cweb etfecn brokers usa Ikena Oncology, Inc. (NASDAQ:IKNA) Achilles Therapeutics plc (NASDAQ:ACHL) Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates . Photo by Thought Catalog on Unsplash. american semiconductor stock Insider Trades Ideas Short Interest Ikena Oncology Stock (NASDAQ:IKNA), Quotes and News Summary Ikena Oncology Stock (NASDAQ: IKNA) stock price, news, charts, …BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...